The Society of Gynecologic Oncologists Annual Meeting o

Three studies examine a treatment, a diagnostic, and the risk of thromboembolism after pelvic surgery, respectively.

Moroney and colleagues discussed the preliminary results of a novel phase I combination of liposomal doxorubicin, bevacizumab, and temsirolimus.

A study provided evidence that certain tumors can safely be monitored with ultrasound for years without raising the risk of ovarian cancer.

Women with uterine cancer who are treated with laparoscopy have a 3-year rate of overall survival similar to that of women who undergo traditional laparotomy.

Some patients with ovarian cancer benefit from adding a taxane to a platinum-based chemotherapy, but the regimen presents increased risk.

Gynecologic oncologists are advancing a treatment method that shows great promise in extending PFS and OS for women with certain advanced gynecologic cancers.

Ware and associates described a multi-institutional experience that examined the American Society of Obstetricians referral guidelines for a pelvic mass.

Three highly provocative papers from the Gynecologic Oncology Group were presented during the initial plenary session of SGO.

A combination regimen of docetaxel and carboplatin prolongs PFS in recurrent ovarian cancer but decreases quality of life.

Gardasil, a vaccine that prevents cervical cancer, also reduces the likelihood of recurrence after surgery by 40%.